Economic Evaluation of Abiraterone in Metastatic Castration-Resistant Prostate Cancer in Patients With None/Mild Symptoms After Failure of Androgen Deprivation Therapy (original) (raw)

of prostate cancer patients with bone metastases (patients who were specifically coded as "Castration-resistant prostate cancer" (ICD-10, C61) and "8848040" (Japan MEDIS-DC)), who had been treated with ADT and a CRPC-targeted treatment (according to approved indication). Results: 276 patients were identified, with a mean age of 71.0 y.o (S.D. 8.7). Visceral metastasis was present in 43.8% of the patients, with the most common site being the lungs (34.4%). The mean treatment period for mCRPC was 34 months. 87.4% had undergone medical Androgen Deprivation Therapy (ADT), with 5.8% undergoing surgical ADT. Radiation therapy was given to 29.3% of patients, and 40% had been treated with opioids. 89.5% of the patients had undergone bone scanning. There were an average number of 67 outpatient visits and 2.8 inpatient admissions per patient during the treatment period. A mean of 9.9 laboratory and imaging examinations in the year prior to CRPC diagnosis was observed, increasing to a mean 28.6 one year post-diagnosis. The most common diagnostic and imaging combination done prior to mCRPC diagnosis was bone scintigraphy, CT, PSA, and blood biochemistry test. Mean per patient monthly costs increased 6-fold from prior to CRPC to post-CRPC diagnosis. ConClusions: Metastatic castration-resistant prostate cancer brings about increased resource use for patients in Japan, with a threefold increase in diagnostic and monitoring tests, increased hospital visits, and increased monthly per patient costs as a result of diagnosis.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact